Table 3.
Sick Leave After First Vaccinationa | Sick Leave After Second Vaccinationa | |||
---|---|---|---|---|
Total (%) (n = 239) | Crude OR (95% CI) | Total (%) (n = 539) | Crude OR (95% CI) | |
Age group | ||||
15–29 y (reference) | 72 (30.1) | 1 | 155 (28.8) | 1 |
30–39 y | 53 (22.2) | 0.77 (0.53–1.13) | 119 (22.1) | 0.78 (0.59–1.03) |
40–49 y | 50 (20.9) | 0.72 (0.49–1.06) | 129 (23.9) | 0.86 (0.66–1.13) |
50–59 y | 55 (23.0) | 0.64 (0.44–0.93) | 112 (20.8) | 0.55 (0.42–0.73) |
60–69 y | 9 (3.8) | 0.33 (0.16–0.67) | 24 (4.5) | 0.36 (0.23–0.57) |
Sex | ||||
Male (reference) | 47 (19.7) | 1 | 120 (22.3) | 1 |
Female | 191 (79.9) | 1.69 (1.21–2.35) | 419 (77.7) | 1.50 (1.20–1.89) |
Divers | 1 (0.4) | … | 0 | … |
Occupational activity | ||||
Nurse (reference) | 71 (29.7) | 1 | 193 (35.8) | 1 |
Physician | 23 (9.6) | 0.58 (0.36–0.95) | 68 (12.6) | 0.59 (0.43–0.80) |
Other occupation with direct patient contact | 54 (22.6) | 1.27 (0.87–1.85) | 110 (20.4) | 0.90 (0.69–1.18) |
Other occupation without direct patient contact | 91 (38.1) | 1.37 (0.99–1.91) | 168 (31.2) | 0.87 (0.68–1.10) |
Vaccine | ||||
BNT162b2 (reference) | 51 (21.3) | 1 | 408 (75.7) | 1 |
mRNA-1273 | 18 (7.5) | 2.49 (1.43–4.34) | 120 (22.3) | 2.37 (1.83–3.06) |
ChAdOx1-S | 167 (69.9) | 28.94 (20.43–41.00) | 11 (2.0) | 0.38 (0.20–0.71) |
Ad26.COV2-S | 3 (1.3) | 32.24 (6.35–163.60) | … | … |
BMI (n = 237/535) | … | 1.00 (0.97–1.02) | … | 0.98 (0.96–1.00) |
Any chronic disease | 58 (24.3) | 1.13 (0.83–1.55) | 135 (25.0) | 1.22 (0.98–1.53) |
Immunosuppression | 7 (2.9) | 1.19 (0.54–2.66) | 13 (2.4) | 0.94 (0.50–1.76) |
Antipyretic medication before first vaccination | 55 (23.0) | 5.48 (3.83–7.84) | … | … |
Antipyretic medication before second vaccination | … | … | 43 (8.0) | 1.09 (0.76–1.56) |
Significant ORs (95% CI) are presented in bold.
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Percentages may not total 100 because of rounding.